Relmada Therapeutics with ticker code (RLMD) now have 6 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The target price ranges between 75 and 38 and has a mean target at 62.83. Now with the previous closing price of 32.87 this would imply there is a potential upside of 91.1%. There is a 50 day moving average of 34.12 while the 200 day moving average is 38.03. The company has a market capitalisation of $534m. Find out more information at: http://www.relmada.com
The potential market cap would be $1,021m based on the market concensus.
Relmada Therapeutics, a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics was founded in 2004 and is headquartered in New York, New York.
